Michael Sperling, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant
    Ineligible company: 
    Medtronic
    Topic: 
    thermal ablation
    Date added: 
    12/21/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    01/25/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant
    Ineligible company: 
    Neurelis
    Topic: 
    research design
    Date added: 
    12/21/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    01/25/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant
    Ineligible company: 
    Johnson & Johnson
    Topic: 
    research design
    Date added: 
    12/21/2023
    Mitigation strategy: 
    Peer review
    Relationship end date: 
    05/01/2023
    Date reviewed: 
    01/25/2024
  • Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Medtronic
    Topic: 
    device development
    Date added: 
    12/21/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    01/25/2024
  • Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Takeda
    Topic: 
    drug development
    Date added: 
    12/21/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    01/25/2024
  • Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Xenon
    Topic: 
    drug development
    Date added: 
    12/21/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    01/25/2024
  • Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Cerevel
    Topic: 
    drug development
    Date added: 
    12/21/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    01/25/2024
  • Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    UCB Pharma
    Topic: 
    drug development
    Date added: 
    12/21/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    01/25/2024
  • Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Janssen
    Topic: 
    drug development
    Date added: 
    12/21/2023
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    01/25/2024
  • Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Equilibre
    Topic: 
    drug development
    Date added: 
    12/21/2023
    Mitigation strategy: 
    Peer review
    Relationship end date: 
    11/01/2023
    Date reviewed: 
    01/25/2024

Pages

Return to 0270_Sutter Neuroscience Grand Rounds_What is a Seizure?_Live